重组人血管内皮抑制素联合GP方案治疗晚期非小细胞肺癌  

Clinical study of recombinant human endostatin with GP regimen in the treatment of advancednon-small-cell lung cancer

作　　者：顾明[1] 耿利民[1] 孙红祎[1] 

机构地区：[1]东南大学医学院附属盐城医院肿瘤内科,江苏盐城224001

出　　处：《肿瘤研究与临床》2011年第10期690-692,共3页Cancer Research and Clinic

摘　　要：目的 评价重组人血管内皮抑制素（商品名：恩度）联合吉西他滨加顺铂（GP）方案治疗晚期非小细胞肺癌（ NSCLC）的疗效和安全性.方法 采用非随机同期对照的方法,以接受重组人血管内皮抑制素联合化疗的NSCLC患者32例为试验组,单纯GP方案化疗者40例为对照组.比较两组有效率（RR）、临床受益率（ CBR）、肿瘤进展时间（TTP）、生活质量（QOL）及安全性.结果 试验组和对照组的总RR分别为40.6％（13/32）和20.0％（8/40）,差异无统计学意义（x2=3.66,P=0.07）,总CBR分别为68.8％（22/32）和42.5％（17/40）,差异有统计学意义（x2 =4.93,P=0.034）,总的中位TTP分别为5.2个月和3.9个月,差异有统计学意义（P=0.042）.试验组与对照组不良反应的发生率差异无统计学意义（P＞0.05）.结论 重组人血管内皮抑制素联合GP方案能明显提高晚期NSCLC的RR、CBR及中位TTP,安全性好。Objective To evaluate the efficacy and security of combined recombinant human endostatin with GP chemotherapy for the treatment of advanced non-small-cell lung cancer （NSCLC）.Methods Non- randomized concurrent control was used.32 patients were treated by recombinant human endostatin combined with chemotherapy as test group,40 patients of control group only received chemotherapy.The response rate （RR）,the clinical benefit rate （CBR） and the time to progression （TTP） were observed.Results The total RR in two groups were 40.6 % and 20.0 % （x2 =3.66,P =0.07）.The total CBR were 68.8 % and 42.5 % （x2 =4.93,P =0.034）.The total time to progression were 5.2 months and 3.9 months （P =0.042）.Incidence of adverse reactions of experimental group and control group was no significant difference.Conclusion Combined recombinant human endostatin and chemotherapy can improve the curative effect （RR,CBR and TTP） of advanced NSCLC

关 键 词：癌 非小细胞肺癌 血管抑制素类 药物疗法 联合 

分 类 号：R734.2[医药卫生—肿瘤]